Skip to main content
Erschienen in: Medical Oncology 4/2010

01.12.2010 | Original Paper

Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes

verfasst von: Tadashi Terada

Erschienen in: Medical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

An extremely rare case of primary small cell carcinoma of the pleura with an emphasis on KIT and platelet-derived growth factor receptor-α (PDGFRA) genes is reported here. A 67-year-old man underwent left testicular orchiectomy because of a testicular tumor. The tumor was immunohistochemically shown to be diffuse large B-cell lymphoma. The patient was treated with chemotherapy and radiation and followed up in our hospital. Eight years after the orchiectomy, the patient (75 years old) developed left pleural tumor and pleural effusion, and a biopsy was performed. The biopsy revealed a medullary malignant tumor consisting of small round and spindle cells. The following three possibilities were considered: recurrent lymphoma, mesothelioma, and small cell carcinoma. Immunohistochemically, the tumor cells were positive for cytokeratin, synaptophysin, CD56, KIT, and PDGFRA, but negative for CEA, cytokeratin 5/6, neuron-specific enolase, chromogranin, CD45, CD3, CD20, CD45RO, CD15, CD30, calretinin, WT-1, B72.3, D2-40, and TTF-1. Therefore, a diagnosis of pleural small cell carcinoma was made. A molecular genetic analysis using PCR-direct sequencing identified no mutations of KIT (exons 9, 11, 13, and 17) and PDGFRA (exons 12 and 18) genes. The patient was treated with chemotherapy (cisplatin) and radiation (50 Gray). The present case is the first reported case of primary small cell carcinoma of the pleura with an examination of KIT and PDGFRA expressions and KIT and PDGFRA gene mutations.
Literatur
1.
2.
Zurück zum Zitat Schrinkewitch P, Gasser B, Wihlm JM, Pauri G, Quoix E. Small cell carcinoma of the pleura: a case report. Lung Cancer. 1996;16:87–94.CrossRef Schrinkewitch P, Gasser B, Wihlm JM, Pauri G, Quoix E. Small cell carcinoma of the pleura: a case report. Lung Cancer. 1996;16:87–94.CrossRef
3.
Zurück zum Zitat van der Heijiden HF, Heijidra YE, Bulten J, Festen J. Pleural small cell carcinoma in pre-existing asbestos related pleural disease. Lung Cancer. 2002;35:91–4.CrossRef van der Heijiden HF, Heijidra YE, Bulten J, Festen J. Pleural small cell carcinoma in pre-existing asbestos related pleural disease. Lung Cancer. 2002;35:91–4.CrossRef
4.
Zurück zum Zitat Terada T. Primary small cell carcinoma of the mediastinum: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol. 2009;26:247–50.PubMedCrossRef Terada T. Primary small cell carcinoma of the mediastinum: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol. 2009;26:247–50.PubMedCrossRef
5.
Zurück zum Zitat Terada T. Autopsy case of primary small cell carcinoma of the urinary bladder: KIT and PDGFRA expression and mutations. Pathol Int. 2009;59:247–50.PubMedCrossRef Terada T. Autopsy case of primary small cell carcinoma of the urinary bladder: KIT and PDGFRA expression and mutations. Pathol Int. 2009;59:247–50.PubMedCrossRef
6.
Zurück zum Zitat LaPoint RJ, Bourne PA, Wang HL, Xu H. Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. Appl Immunohistochem Mol Morphol. 2007;15:401–6.PubMedCrossRef LaPoint RJ, Bourne PA, Wang HL, Xu H. Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung. Appl Immunohistochem Mol Morphol. 2007;15:401–6.PubMedCrossRef
7.
Zurück zum Zitat Lopes-Martin A, Ballenstin C, Garcia-Carbonero R, Castano A, Lopez-Rios F, Lopes-Encuentra A, et al. Prognostic value of KIT expression in small cell lung carcinoma. Lung Cancer. 2007;56:405–13.CrossRef Lopes-Martin A, Ballenstin C, Garcia-Carbonero R, Castano A, Lopez-Rios F, Lopes-Encuentra A, et al. Prognostic value of KIT expression in small cell lung carcinoma. Lung Cancer. 2007;56:405–13.CrossRef
8.
Zurück zum Zitat Micke P, Basral M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, et al. Characterization of c-kit expression in small cell lung carcinoma: prognostic and therapeutic implications. Clin Cancer Res. 2003;9:188–94.PubMed Micke P, Basral M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, et al. Characterization of c-kit expression in small cell lung carcinoma: prognostic and therapeutic implications. Clin Cancer Res. 2003;9:188–94.PubMed
9.
Zurück zum Zitat Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, et al. Analysis of c-kit expression in small cell lung carcinoma: prevalence and prognostic implications. Lung Cancer. 2006;52:343–7.PubMedCrossRef Camps C, Sirera R, Bremnes RM, Garde J, Safont MJ, Blasco A, et al. Analysis of c-kit expression in small cell lung carcinoma: prevalence and prognostic implications. Lung Cancer. 2006;52:343–7.PubMedCrossRef
10.
Zurück zum Zitat Rossi G, Cavazza A, Marchioni A, Miggaldi M, Bavierli M, Fracciolongo N, et al. KIT expression in small cell carcinoma of the lung: effects of chemotherapy. Mod Pathol. 2003;16:1041–7.PubMedCrossRef Rossi G, Cavazza A, Marchioni A, Miggaldi M, Bavierli M, Fracciolongo N, et al. KIT expression in small cell carcinoma of the lung: effects of chemotherapy. Mod Pathol. 2003;16:1041–7.PubMedCrossRef
11.
Zurück zum Zitat Naeem M, Dahiya M, Clark JI, Creech SD, Alkin S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implications for prognosis. Hum Pathol. 2002;33:1182–7.PubMedCrossRef Naeem M, Dahiya M, Clark JI, Creech SD, Alkin S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implications for prognosis. Hum Pathol. 2002;33:1182–7.PubMedCrossRef
12.
Zurück zum Zitat Mojica WD, Saxena R, Starostik P, Cheney RT. CD117+ small cell lung cancer lacks the asp 816 val point mutation in exon 17. Histopathology. 2005;47:517–22.PubMedCrossRef Mojica WD, Saxena R, Starostik P, Cheney RT. CD117+ small cell lung cancer lacks the asp 816 val point mutation in exon 17. Histopathology. 2005;47:517–22.PubMedCrossRef
13.
Zurück zum Zitat Boldrini L, Ursino S, Gisfredi S, Faviana P, Donati V, Camcci T, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res. 2004;15:4101–8.CrossRef Boldrini L, Ursino S, Gisfredi S, Faviana P, Donati V, Camcci T, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res. 2004;15:4101–8.CrossRef
14.
Zurück zum Zitat Burger H, Den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-kit/CD117-positive SCLC tumor specimens. Eur J Cancer. 2003;39:793–9.PubMedCrossRef Burger H, Den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-kit/CD117-positive SCLC tumor specimens. Eur J Cancer. 2003;39:793–9.PubMedCrossRef
15.
Zurück zum Zitat Sihto H, Sarlomo-Rikara M, Tynnienen O, Tanner M, Andersson LC, Franssila K, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005;23:49–57.PubMedCrossRef Sihto H, Sarlomo-Rikara M, Tynnienen O, Tanner M, Andersson LC, Franssila K, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005;23:49–57.PubMedCrossRef
16.
17.
Zurück zum Zitat Osota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diang Pathol. 2006;23:91–102.CrossRef Osota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diang Pathol. 2006;23:91–102.CrossRef
18.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumor: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMed Miettinen M, Lasota J. Gastrointestinal stromal tumor: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMed
19.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumor. Science. 1998;279:577–80.PubMedCrossRef Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumor. Science. 1998;279:577–80.PubMedCrossRef
20.
Zurück zum Zitat Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumor. Gastroenterology. 2003;125:660–7.PubMedCrossRef Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumor. Gastroenterology. 2003;125:660–7.PubMedCrossRef
21.
Zurück zum Zitat Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissue, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13:205–20.PubMedCrossRef
22.
Zurück zum Zitat Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int. 2002;52:740–6.PubMedCrossRef
23.
Zurück zum Zitat Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;271:271–5.CrossRef Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med. 2005;271:271–5.CrossRef
24.
Zurück zum Zitat Terada T. Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes. Int J Gynecol Oncol. 2009;28:29–34. Terada T. Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes. Int J Gynecol Oncol. 2009;28:29–34.
25.
Zurück zum Zitat Terada T. Primary extragastrointestinal stromal tumor of the transverse mesocolon without c-kit mutations but with PDGFRA mutations. Med Oncol. 2009;26:233–7.PubMedCrossRef Terada T. Primary extragastrointestinal stromal tumor of the transverse mesocolon without c-kit mutations but with PDGFRA mutations. Med Oncol. 2009;26:233–7.PubMedCrossRef
26.
Zurück zum Zitat Terada T. Primary multiple extragastrointestinal stromal tumors of the omentum with different mutations of c-kit gene. World J Gastroenterol. 2008;14:7256–9.PubMedCrossRef Terada T. Primary multiple extragastrointestinal stromal tumors of the omentum with different mutations of c-kit gene. World J Gastroenterol. 2008;14:7256–9.PubMedCrossRef
27.
Zurück zum Zitat Terada T. Primary small cell carcinoma of the ureter: a case report involving immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Pathology 2009. Terada T. Primary small cell carcinoma of the ureter: a case report involving immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Pathology 2009.
Metadaten
Titel
Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes
verfasst von
Tadashi Terada
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9345-2

Weitere Artikel der Ausgabe 4/2010

Medical Oncology 4/2010 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.